Document is current
Any future updates will be listed below
-
Authors
Flitsch, Lea Jessica https://orcid.org/0000-0002-2746-6519
Börner, Kathleen https://orcid.org/0000-0001-7705-9375
Stüllein, Christian
Ziegler, Simon
Sonntag-Buck, Vera
Wiedtke, Ellen
Semkova, Vesselina
Au Yeung, Si Wah Christina
Schlee, Julia
Hajo, Mohamad
Mathews, Mona https://orcid.org/0000-0002-8617-2553
Ludwig, Beatrice Stefanie
Kossatz, Susanne
Kessler, Horst https://orcid.org/0000-0002-7292-9789
Grimm, Dirk https://orcid.org/0000-0001-6227-5665
Brüstle, Oliver https://orcid.org/0000-0002-1277-0980
-
Funding
Funding for this research was provided by:
Deutsches Zentrum für Infektionsforschung (TTU-HIV 04.815, TTU-HIV 04.815)
Deutsche Forschungsgemeinschaft (240245660)
Horizon 2020 (874758)
National Institutes of Health (R01 NS100514)
Rheinische Friedrich-Wilhelms-Universität Bonn
- License Information
-
More Information
Article History
Received: 31 August 2021
Accepted: 9 May 2022
First Online: 19 May 2022
Competing interests
: D.G. is a co-founder of AaviGen GmbH. O.B. is co-founder, shareholder and CEO of LIFE and BRAIN GmbH. K.B. and D.G. are inventors on pending patent applications related to the AAV variants used in this work, as are M.M. and O.B. for the differentiation paradigm used to produce iPSdMiG. C.S. is co-founder, shareholder and chief execution officer of CLADIAC GmbH and SSE. S.Z. is co-founder and shareholder of CLADIAC GmbH and KINSYS GmbH. All other authors declare no competing interests.
